What You Should Know:
– Eli, a health technology company, announced it has raised $12M in Series A funding to scale its vision for real-time hormone monitoring led by BDC Capital’s Thrive Venture Fund, with participation from Muse Capital, TELUS Global Ventures, and other key investors. This brings the company’s total funding to $20M.
– The new capital will be used to bring the Hormometer™—the world’s first instant hormone monitoring system—to millions of people, addressing a significant gap in personalized health.
The Problem: Challenges with Hormone Health
Hormones are fundamental to nearly every aspect of health, from stress, energy, and sleep to fertility and longevity. Yet, traditional testing methods provide only a single snapshot in time, often days or weeks after symptoms appear. This is a critical limitation, as hormones like cortisol can fluctuate by as much as 100% in a single hour.
This “snapshot” approach has led to a widespread and underdiagnosed health crisis:
- 1 in 3 adults show signs of cortisol dysregulation.
- 60% of adults will experience symptoms related to hormone imbalances.
Despite how common these issues are, the tools to understand our hormones in real time have not existed—until now.
The Solution: The Hormometer™
Eli has built what was missing: a way to track hormones instantly using just saliva and a smartphone. The Hormometer™ is the first real-time hormone monitor, providing results in minutes without labs, sample shipments, or waiting. The new layer of digital health intelligence gives users a live view of their biology, providing not just a number, but context. This allows individuals to understand what’s happening in their bodies now and take immediate, informed action.
The Hormometer™ is the result of years of R&D and deep technology development. Eli has built an end-to-end system that includes:
- Biochemistry designed specifically for microfluidics.
- AI and machine learning to interpret dynamic hormone signals.
- Custom hardware manufactured in-house.
- 12+ patent-pending innovations across science, engineering, and design.
After years of development, Eli has reached commercial readiness, completed third-party validations, and is currently running a private beta with early adopters.
Expansion Plans
The new funding will enable Eli to accelerate its growth, with a focus on:
- Scaling production of the Hormometer™.
- Expanding access to a wider audience.
- Unlocking more biomarkers, starting with cortisol and progesterone.
